Equities

Aker Biomarine ASA

Aker Biomarine ASA

Actions
Consumer Staples Food Producers
  • Price (NOK)52.50
  • Today's Change1.80 / 3.55%
  • Shares traded41.21k
  • 1 Year change+18.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aker Biomarine ASA is a Norway-based biotech innovator and Antarctic krill-harvesting company. It consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.

  • Revenue in NOK (TTM)2.87bn
  • Net income in NOK-15.46m
  • Incorporated2014
  • Employees373.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yaprak Sut ve Besi Cftlklr Sny v Tcrt AS87.02m29.83m2.25bn60.0075.4215.8966.4725.856.546.5419.0931.060.60317.6116.194,674,251.0020.6727.0026.1134.5523.5321.3234.2742.351.25--0.103317.9021.1053.2989.70121.6073.44--
Kaldvik AS733.57m33.64m3.50bn175.00104.141.0621.824.770.27460.27466.0027.090.1432.928.184,191,834.000.63930.67130.69740.783774.7156.554.473.762.910.74460.33790.00-47.5313.79213.22135.0238.00--
Anglo-Eastern Plantations PLC4.03bn645.05m3.81bn15.33k5.900.67094.420.94461.171.297.2910.270.586614.2827.4118,785.539.9012.2511.8515.8022.2325.1216.8719.676.19--0.00188.32-17.138.14-45.4634.891.9958.49
Aker Biomarine ASA2.87bn-15.46m4.48bn373.00--2.148.011.56-0.175625.9732.7123.890.42421.223.427,688,373.00-0.2287-1.00-0.2631-1.1431.1136.94-0.5391-2.561.35-1.130.4419--20.9616.81-190.00---5.24--
Acomo NV14.77bn414.09m6.12bn1.13k14.761.289.920.41441.201.2042.8513.891.613.507.391,100,136.004.506.216.459.7814.1314.192.803.880.94338.050.376158.54-11.0112.58-27.355.013.442.83
Data as of Nov 21 2024. Currency figures normalised to Aker Biomarine ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

4.45%Per cent of shares held by top holders
HolderShares% Held
Arctic Asset Management ASas of 30 Sep 20241.60m1.83%
DNB Asset Management ASas of 13 Jul 2023645.65k0.74%
OP Asset Management Ltd.as of 13 Jul 2023518.25k0.59%
Aktia Bank Plc (Investment Management)as of 31 Dec 2023400.00k0.46%
Eika Kapitalforvaltning ASas of 31 Oct 2024300.00k0.34%
Mandatum Fund Management SAas of 31 Dec 2023287.58k0.33%
Dimensional Fund Advisors LPas of 07 Nov 202467.32k0.08%
Union Bancaire Priv�e, UBP SA (UK)as of 28 Jun 202447.71k0.05%
Dimensional Fund Advisors Ltd.as of 31 Aug 202416.51k0.02%
Gesiuris Asset Management SGIIC SAas of 30 Jun 202415.25k0.02%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.